EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal serum metabolomics predicts therapeutic outcome in acute myeloid leukemia

Qing Cai, Wanying Liu, Changjian Yan, Jiazheng Li, Yan Huang, Xiang Li, Qinwen Yang, Xiaoyu Wei, Huilin Yang, Guanbin Zhang, Ting Yang, Yanxin Chen und 1 weitere

Translational Oncology · 2025-12 · 62 · 102567

DOI: 10.1016/j.tranon.2025.102567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2025-12. Verfasst von Qing Cai und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Road, Quanzhou, Fujian 362000, China; Institute of Precision Medicine, F…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fujian Provincial Finance Department, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with approximately 50 % of patients failing to achieve remission during initial treatment and progressing to refractory AML. Metabolomics, a technology directly linked to clinical phenotypes, offers more precise susceptibility biomarkers compared to genomics and epigenetics. Our study compares metabolic samples collected at multiple time points pre- and after-chemotherapy, performs longitudinal integrated analysis to characterize dynamic alterations, and assesses the temporal impacts of therapeutic responses. Four metabolites-pseudouridine, O-phospho-L‑serine, l-aspartate, and 2-deoxy-d-ribose 1-phosphate-were significantly elevated in AML patients, mechanistically linking dysregulated nucleotide biosynthesis and adaptive amino acid metabolic reprogramming to leukemogenic proliferation.Longitudinal sampling during AML treatment revealed temporal metabolic changes, identifying key metabolites and pathways associated with therapeutic responses.By integrating pre- and after-treatment metabolic index with clinical indicators, we developed predictive models for treatment outcomes. The pre-treatment metabolic model (AUC=0.9143, 95 % CI 0.816-1) and the after-treatment metabolic index (AUC=0.9136, 95 % CI 0.83-1) both demonstrated excellent predictive performance for AML therapeutic outcomes. In conclusion, our findings underscore the potential of targeting glycolipid synthesis and amino acid metabolism to improve clinical outcomes. The dynamic metabolic reprogramming landscape serves as a robust indicator of AML treatment efficacy, offering novel directions for precision therapy in AML.

Schlagwörter

Stichwörter der Autor:innen

Acute myeloid leukemiaDynamic analysisMetabolic modelMetabolomics

Autor:innen und Institutionen

  • The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Road, Quanzhou, Fujian 362000, China; Institute of Precision Medicine, Fujian Medical University, Fuzhou, Fujian 350001, China.
  • The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Road, Quanzhou, Fujian 362000, China.
  • ZhangZhou Municipal Hospital of Fujian Province, No. 59, Shengli Road, Zhangzhou, Fujian 363000, China.
  • Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, Fujian 350001, China.
  • Institute of Precision Medicine, Fujian Medical University, Fuzhou, Fujian 350001, China; School of Intelligent Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610000, China; Department of…
  • Institute of Precision Medicine, Fujian Medical University, Fuzhou, Fujian 350001, China; The Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Med…

Förderung

  • Fujian Provincial Finance Department
  • National Natural Science Foundation of China

Zitieren

APA

Cai, Q., Liu, W., Yan, C., Li, J., Huang, Y., Li, X., Yang, Q., Wei, X., Yang, H., Zhang, G., Yang, T., Chen, Y., & Hu, J. (2025). Longitudinal serum metabolomics predicts therapeutic outcome in acute myeloid leukemia. Translational Oncology, 62, 102567. https://doi.org/10.1016/j.tranon.2025.102567

Vancouver

Cai Q, Liu W, Yan C, Li J, Huang Y, Li X, et al. Longitudinal serum metabolomics predicts therapeutic outcome in acute myeloid leukemia. Translational Oncology. 2025;62:102567. doi:10.1016/j.tranon.2025.102567

BibTeX
@article{Cai2025,
  author = {Cai, Qing and Liu, Wanying and Yan, Changjian and Li, Jiazheng and Huang, Yan and Li, Xiang and Yang, Qinwen and Wei, Xiaoyu and Yang, Huilin and Zhang, Guanbin and Yang, Ting and Chen, Yanxin and Hu, Jianda},
  title = {Longitudinal serum metabolomics predicts therapeutic outcome in acute myeloid leukemia},
  journal = {Translational Oncology},
  year = {2025},
  volume = {62},
  pages = {102567},
  doi = {10.1016/j.tranon.2025.102567}
}
Kostenlos starten →